PT - JOURNAL ARTICLE AU - Surendra, Henry AU - Elyazar, Iqbal RF AU - Djaafara, Bimandra A AU - Ekawati, Lenny L AU - Saraswati, Kartika AU - Adrian, Verry AU - Widyastuti, AU - Oktavia, Dwi AU - Salama, Ngabila AU - Lina, Rosa N AU - Andrianto, Adhi AU - Lestari, Karina D AU - Burhan, Erlina AU - Shankar, Anuraj H AU - Thwaites, Guy AU - Baird, J. Kevin AU - Hamers, Raph L. TI - Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: a hospital-based retrospective cohort study AID - 10.1101/2020.11.25.20235366 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.25.20235366 4099 - http://medrxiv.org/content/early/2020/11/30/2020.11.25.20235366.short 4100 - http://medrxiv.org/content/early/2020/11/30/2020.11.25.20235366.full AB - Background Data on COVID-19-related mortality and associated factors from low-resource settings are scarce. This study examined clinical characteristics and factors associated with in-hospital mortality of COVID-19 patients in Jakarta, Indonesia, from March 2 to July 31, 2020.Methods This retrospective cohort included all hospitalised patients with PCR-confirmed COVID-19 in 55 hospitals. We extracted demographic and clinical data, including hospital outcomes (discharge or death). We used Cox regression to examine factors associated with mortality.Findings Of 4265 patients with a definitive outcome by July 31, 3768 (88%) were discharged and 497 (12%) died. The median age was 46 years (IQR 32–57), 5% were children, and 31% had at least one comorbidity. Age-specific mortalities were 11% (7/61) for <5 years; 4% (1/23) for 5-9; 2% (3/133) for 10-19; 2% (8/638) for 20-29; 3% (26/755) for 30-39; 7% (61/819) for 40-49; 17% (155/941) for 50-59; 22% (132/611) for 60-69; and 34% (96/284) for ≥70. Risk of death was associated with higher age; pre-existing hypertension, cardiac disease, chronic kidney disease or liver disease; clinical diagnosis of pneumonia; multiple (>3) symptoms; and shorter time from symptom onset to admission. Patients <50 years with >1 comorbidity had a nearly six-fold higher risk of death than those without (adjusted hazard ratio 5·50, 95% CI 2·72-11·13; 27% vs 3% mortality).Interpretation Overall mortality was lower than reported in high-income countries, probably due to younger age distribution and fewer comorbidities. However, deaths occurred across all ages, with >10% mortality among children <5 years and adults >50 years.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding StatementThis work was funded by the Wellcome Trust, UK (106680/Z/14/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Health Research Ethics Committee of the National Institute of Health Research and Development, Ministry of Health Indonesia (LB.02.02/2/KE.554/2020). The requirement for patient consent was waived as this was a secondary analysis of anonymised routine surveillance data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAfter publication, the datasets used for this study will be made available to others on reasonable requests to the corresponding author, including a detailed research proposal, study objectives and statistical analysis plan. Deidentified participant data will be provided after written approval from the corresponding author and the Jakarta Health Office.